BACK

Kelly Curtin

Kelly Curtin

Managing Director

London Office  |  kelly.curtin@torreya.com   |   +44 (0) 207 451 4564

Kelly Curtin, a Managing Director on Torreya’s European team, advises clients on strategic transactions across the life sciences industry. She has 20 years of experience in investment banking, primarily in the healthcare industry.

Before joining Torreya in 2014, Kelly was a Director in Credit Suisse’s Mergers & Acquisitions group in Chicago and London. Notable transactions on which she advised prior to joining Torreya include the management buy-out of Bilim Pharmaceuticals, the $21.3 billion sale of Synthes Inc. to Johnson & Johnson, the $889 million sale of Plus Orthopaedics to Smith & Nephew, the acquisition of privately held Arakis biopharmaceutical company by Japan’s Sosei Ltd., and the $2.4 billion sale of Finland’s Instrumentarium to General Electric. She has also worked on debt and equity financings for many life sciences companies, including Advent, Lonza, Nobel Biocare, Nycomed, Gerresheimer, Phonak, SkyePharma, and Fresenius.

Kelly holds a B.A. in law, jurisprudence and social thought from Amherst College.

She serves on the committee for the Great Ormond Street Hospital Christmas Carol Concert.

Selected Transactions

Midatech Pharma PLC
Sale of Midatech Pharma US Inc. to Kanwa Holdings LP, an affiliate of Barings LLC
None
Up to $19 million
November 2018
Lysogene
Licensing of ex European rights for LYS-SAF302 to
Sarepta Therapeutics
$15 million upfrontwith up to $110m in additional payments plus royalties
October 2018
Shield Therapeutics
Licensing Agreement for Feraccru® in Europe, Australia and New Zealand with
Norgine
£11 million upfront(plus up to £54.5m in milestones and 25-40% royalties)
September 2018
Midatech Pharma
Acquisition of
Dara Biosciences
Up to $30 million
December 2015